EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Science
Authors
Keywords
Abstract

Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. EGFR mutations were found in additional lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. These results suggest that EGFR mutations may predict sensitivity to gefitinib.

Year of Publication
2004
Journal
Science
Volume
304
Issue
5676
Pages
1497-500
Date Published
2004 Jun 04
ISSN
1095-9203
URL
DOI
10.1126/science.1099314
PubMed ID
15118125
Links